Low-dose long-term oral idarubicin in maintenance treatment of elderly acute myeloid leukemia

Haematologica

Volumn 82, Issue SUPPL.5, 1997, Pages 4-8

  Musso, Maurizio ^a,b   Porretto, Ferdinando ^a   Crescimanno, Alessandra ^a   Bondì, Francesca ^a   Polizzi, Vita ^a   Scalone, Renato ^a   Tolomeo, Manlio ^a   Mariani, Guglielmo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Cattedra ed UO di Ematologia con trapianto   (Italy)

Author keywords

AML; Apoptosis; Elderly; Idarubicin

Indexed keywords

DNA; IDARUBICIN; IDARUBICINOL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; CELL CYCLE; CELL STRAIN HL 60; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MUCOSA INFLAMMATION; NAUSEA; ORAL DRUG ADMINISTRATION; VOMITING;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED;

EID: 0031453923     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Brinker H. Estimate of overall treatment results in acute non lymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 1985; 69:5-11.
2. Cartwright RA, Staines A. Acute leukemias. Epidemiology of Haematological Disease. I. Fleming AT, ed. Bailliére Clin Haematol 1992; 5:1-26.
3. Lowenberg B. Acute myelogeneus leukaemia and myelodysplasia. Bailliére Clin Haematol 1996; 9:147-59.
4. Keating MJ, McCredie KB, Benjamin RS, et al. Treatment of patients over 50 years of age with myelogenous leukemia with a combination of rubidazone and cytosine arabnoside, vincristine and prednisolone (ROAP). Blood 1981; 58:584-91.
5. Swirsky DM, De Bastos M, Parish SE, Rees JKH, Hayhoe FGJ. Features affecting outcome during remission induction of acute myeloid leukemia in 619 adult patients. Br J Haematol 1987; 64:435-53.
6. Campos L, Roualt JP, Oriol P, et al. High expression of BCL-2 protein in acute myelogeneous leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81:3091-6.
7. Liu Yin JA. Acute myeloid leukemia in elderly: biology and treatment. Br J Haematol 1993; 8:361-6.
8. Baudard M, Marie JP, Cadiou M, Viguié V, Zittoun R. Acute myelogenous leukemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86:82-91
9. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis. Blood 1997; 89:243-55.
10. Shiller JC. Post-remission therapy of acute myeloid leukemia in older adults. Leukemia 1996; 10(Suppl. 1):S18-S20.
11. Leoni F, Ciolli S, Pascarella A, et al. Attenuated-dose idarubicin in acute myeloid leukemia of the elderly: pharmacokinetic study and clinical results. Br J Haematol 1995; 90:169-74.
12. Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32:507.
13. Duke RC, Cohen JJ. Morphological and biochemical assay of apoptosis. In: Coligan JE, Kruisbeak AM, eds. Current Protocols in Immunology. New York: John Wiley & Sons; 1992. p. 3171-6.
14. Johnson RE, Ryder WDJ, Liu Yin JA. Validation of a model to predict survival in elderly patients with acute myeloid leukemia. Br J Haematol 1995; 90:954-6.